Compare GoPro Inc (GPRO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Neurocrine Biosciences Inc — how do they compare? GoPro Inc trades at $1.22 (market cap $243.50M), while Neurocrine Biosciences Inc trades at $140.75 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 59× GoPro Inc's market cap, and GoPro Inc is more actively traded (11,527,160 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GPRO | NBIX | |
|---|---|---|
Market Cap | $243.50M | $14.36B |
Volume | 11,527,160 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $2.35 | $185.50 |
52-Week Low | $0.58 | $123.10 |
Typical Hold Time | 45 Days | 23 Days |
Enterprise Value | $302.28M | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.22, down 7.58% on the day, as the company faces significant financial challenges with negative net income margins and declining revenues. Despite recent product recognition for its MISSION 1 series, the stock has been volatile amid merger discussions with Starman Optical and influencer investment interest. Technical indicators show a bullish moving average signal but mixed oscillators, while fundamentals reveal persistent losses and cash burn.
The outlook remains highly speculative with a proposed $1.14 per share buyout offering a potential floor, but ongoing losses and competitive pressures pose substantial risks. Analyst sentiment is mixed with only 21% buy ratings, reflecting skepticism about the company's turnaround prospects despite recent merger excitement.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
